• Annals of surgery · Apr 2016

    Multicenter Study Observational Study

    Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study.

    • Nicholas J Battersby, Peter How, Brendan Moran, Sigmar Stelzner, Nicholas P West, Graham Branagan, Joachim Strassburg, Philip Quirke, Paris Tekkis, Bodil Ginnerup Pedersen, Mark Gudgeon, Bill Heald, Gina Brown, and MERCURY II Study Group.
    • *Pelican Cancer Foundation, Basingstoke, United Kingdom †North Hampshire Hospital, Basingstoke, United Kingdom ‡Dresden-Friedrichstadt General Hospital, Dresden, Germany §Pathology & Tumor Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom ¶Salisbury District Hospital, Salisbury, United Kingdom ||Vivantes im Friedrichshain, Berlin, Germany **The Royal Marsden NHS Foundation Trust, London, United Kingdom ††Aarhus University Hospital, Aarhus, Denmark ‡‡Frimley Park Hospital, Frimley, United Kingdom §§The Academic Department for Radiology, The Royal Marsden Hospital, Sutton, United Kingdom.
    • Ann. Surg. 2016 Apr 1; 263 (4): 751-60.

    ObjectiveThis study aimed to validate a magnetic resonance imaging (MRI) staging classification that preoperatively assessed the relationship between tumor and the low rectal cancer surgical resection plane (mrLRP).BackgroundLow rectal cancer oncological outcomes remain a global challenge, evidenced by high pathological circumferential resection margin (pCRM) rates and unacceptable variations in permanent colostomies.MethodsBetween 2008 and 2012, a prospective, observational, multicenter study (MERCURY II) recruited 279 patients with adenocarcinoma 6 cm or less from the anal verge. MRI assessed the following: mrLRP "safe or unsafe," venous invasion (mrEMVI), depth of spread, node status, tumor height, and tumor quadrant. MRI-based treatment recommendations were compared against final management and pCRM outcomes.ResultsOverall pCRM involvement was 9.0% [95% confidence interval (CI), 5.9-12.3], significantly lower than previously reported rates of 30%. Patients with no adverse MRI features and a "safe" mrLRP underwent sphincter-preserving surgery without preoperative radiotherapy, resulting in a 1.6% pCRM rate. The pCRM rate increased 5-fold for an "unsafe" compared with "safe" preoperative mrLRP [odds ratio (OR) = 5.5; 95% CI, 2.3-13.3)]. Posttreatment MRI reassessment indicated a "safe" ymrLRP in 33 of 113 (29.2%), none of whom had ypCRM involvement. In contrast, persistent "unsafe" ymrLRP posttherapy resulted in 17.5% ypCRM involvement. Further independent MRI assessed risk factors were EMVI (OR = 3.8; 95% CI, 1.5-9.6), tumors less than 4.0 cm from the anal verge (OR = 3.4; 95% CI, 1.3-8.8), and anterior tumors (OR = 2.8; 95% CI, 1.1-6.8).ConclusionsThe study validated MRI low rectal plane assessment, reducing pCRM involvement and avoiding overtreatment through selective preoperative therapy and rationalized use of permanent colostomy. It also highlights the importance of posttreatment restaging.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.